Better Health for All

Blueprint Medicines' core business is focused on discovering, developing, and commercializing kinase medicines for patients with cancer and rare diseases, aiming to improve and extend patients' lives through targeted therapies. The company's products address diseases like systemic mastocytosis, metastatic breast cancer, and gastrointestinal stromal tumor, for which there were previously no approved therapies for specific mutations.

The company has an Equity, Diversity, and Inclusion (ED&I) Committee, which includes 10% of its workforce and 4 executive team members, and supports STEM education programs for underrepresented groups. It also offers a patient support program, YourBlueprint, which provides co-pay assistance with an annual maximum benefit of $25,000.

Fair Pay & Worker Respect

Blueprint Medicines Corporation reported a CEO-to-median employee pay ratio of 35:1 in 2024.

The company achieved a 0% OSHA recordable incident rate at its Cambridge locations in FY2023. Employee engagement, as indicated by Glassdoor ratings, is 4.4 out of 5 stars (88%). The employee turnover rate for 2023 was substantially below the industry average. The company reported no regulatory violations, fines, or enforcement actions related to cGMP, product recalls, or false marketing claims in 2023, and no significant infractions in the past two years. Blueprint Medicines offers comprehensive medical, dental, and vision benefits, including 12-week family leave at 100% pay, a 401(k) plan with company match, and premium access to Modern Health for mental health and lifestyle coaching.

Honest & Fair Business

Blueprint Medicines Corporation has a formal whistleblower protection policy, which includes an anonymous hotline and a process for anonymous and confidential submissions to the board of directors, with international compliance hotline numbers.

However, there is no evidence of independent investigation processes for these reports. The company has a Code of Business Conduct and Ethics that addresses potential risk areas for pharmaceutical manufacturers, including those identified in the 2003 OIG Guidance, and has adopted the Pharmaceutical Research and Manufacturers of America Code. The Code has been updated to include international compliance hotline numbers, employee rights to communicate with the government, and amendments to the fair competition section. Blueprint Medicines has also established a $3,000 annual spending limit for certain spending on individual medical or healthcare professionals in California and declares compliance with California Health & Safety Code §§ 119400-119402. There is no information available regarding regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, or third-party verification of ethical claims.

Kind to Animals

Blueprint Medicines Corporation conducts pre-clinical studies on animals to assess product safety, as evidenced by their use of a systemic mouse model for disease research.

However, the company does not explicitly state an animal testing policy in its public reports, nor does it mention any formal commitments, reduction goals, or oversight mechanisms for animal testing.

No War, No Weapons

No evidence was found in the provided articles to assess Blueprint Medicines Corporation against any of the 'No War, No Weapons' KPIs. The articles either explicitly state they contain no relevant data

or their content was inaccessible, preventing any scoring.

Respect for Cultures & Communities

Blueprint Medicines has no reported cultural appropriation incidents.

The company's operations, focused on biopharmaceuticals, do not appear to directly impact cultural contexts, thus no specific cultural impact assessment protocol is noted. No other KPIs could be scored due to a lack of specific, quantitative evidence in the provided articles that directly maps to the rubric's thresholds.

Zero Waste & Sustainable Products

Blueprint Medicines has implemented over 10 waste reduction initiatives, including a composting program, paper recycling, electronic contract management, eco-friendly printing, and a laboratory materials recycling program in partnership with GreenLabs.

Through this partnership, the company recycled 1,671 pounds of plastic from its Cambridge lab facility in 2023, contributing to a total of 6,684 pounds recycled since 2022. The company maintains a hazardous waste program that complies with local, state, and federal regulations, is registered as a small quantity generator, and pre-treats laboratory wastewater daily before discharge. Routine internal inspections and annual audits of office space and laboratories are conducted to ensure proper handling and safety. The company has not had any waste disposal violations in the past three years. However, Blueprint Medicines has not disclosed specific quantitative waste reduction targets with timelines. While a robust supplier selection program is in place, specific waste reduction or recyclability requirements for all suppliers are not detailed.